Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Revenue (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Revenue data on record, last reported at $13.2 million in Q4 2025.

  • For Q4 2025, Revenue fell 22.44% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $52.0 million, down 18.47%, while the annual FY2025 figure was $52.0 million, 18.47% down from the prior year.
  • Revenue reached $13.2 million in Q4 2025 per OCUL's latest filing, down from $14.5 million in the prior quarter.
  • Across five years, Revenue topped out at $17.1 million in Q4 2024 and bottomed at $7.3 million in Q1 2021.
  • Average Revenue over 5 years is $13.5 million, with a median of $13.4 million recorded in 2023.
  • Peak YoY movement for Revenue: skyrocketed 646.91% in 2021, then decreased 27.59% in 2025.
  • A 5-year view of Revenue shows it stood at $12.3 million in 2021, then increased by 14.36% to $14.1 million in 2022, then grew by 5.16% to $14.8 million in 2023, then grew by 15.42% to $17.1 million in 2024, then decreased by 22.44% to $13.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $13.2 million in Q4 2025, $14.5 million in Q3 2025, and $13.5 million in Q2 2025.